Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema A Systematic Review

被引:89
|
作者
Yilmaz, Taygan [1 ]
Weaver, Christopher D. [1 ]
Gallagher, Micheal J. [2 ]
Cordero-Coma, Miguel [3 ]
Cervantes-Castaneda, Rene A. [4 ]
Klisovic, Dino [5 ]
Lavaque, Alejandro J. [6 ]
Larson, Robin J. [1 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03766 USA
[2] Hermitage Med Clin, Dublin, Ireland
[3] Hosp Leon, Dept Ophthalmol, Leon, Spain
[4] CODET Vis Inst, Tijuana, Mexico
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Oftalmol Cristo Alvarez, San Miguel De Tucuman, Argentina
关键词
RANDOMIZED CLINICAL-TRIAL; RETINOPATHY; PHOTOCOAGULATION;
D O I
10.1016/j.ophtha.2009.02.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Clinical Relevance: Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. Methods and Literature Reviewed: The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. Results: In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. Conclusions: Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:902-913 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 50 条
  • [21] Fluorescein angiography after intravitreal injection of triamcinolone acetonide as treatment of diffuse diabetic macular edema
    Degenring, RF
    Kreissig, I
    Jonas, JB
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U977 - U977
  • [22] Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema
    WANG YushengLI XiaoWANG HaiyanZHANG ZifengLI Manhong and SU Xiaona Department of Ophthalmologythe Eye Institute of Peoples Liberation ArmyXijing HospitalFourth Military Medical UniversityXianShannxi China
    中华医学杂志(英文版), 2011, (03) : 352 - 358
  • [23] Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema
    Wang Yu-sheng
    Li Xiao
    Wang Hai-yan
    Zhang Zi-feng
    Li Man-hong
    Su Xiao-na
    CHINESE MEDICAL JOURNAL, 2011, 124 (03) : 352 - 358
  • [24] Intravitreal triamcinolone for refractory diabetic macular edema
    Martidis, A
    Duker, JS
    Greenberg, PB
    Rogers, AH
    Puliafito, CA
    Reichel, E
    Baumal, C
    OPHTHALMOLOGY, 2002, 109 (05) : 920 - 927
  • [25] Intravitreal triamcinolone acetonide for refractory diabetic macular oedema
    Fernando, AI
    Pandit, JC
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (09) : 421 - 422
  • [26] Combined Intravitreal Bevacizumab and Triamcinolone Injection for Refractory Diabetic Macular Edema
    Bardak, Yavuz
    Bardak, Hatun Handan
    Ekim, Mustafa Muhterem
    OPHTHALMOLOGICA, 2014, 232 : 16 - 16
  • [27] Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection
    Karacorlu, M.
    Ozdemir, H.
    Senturk, F.
    Karacorlu, S. Arf
    Uysal, O.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (04) : 601 - 608
  • [28] Intravitreal injection of triamcinolone - An emerging treatment for diabetic macular edema
    Ip, MS
    DIABETES CARE, 2004, 27 (07) : 1794 - 1797
  • [29] Comparison of Intravitreal Injection of Bevacizumab and Triamcinolone Acetonide in the Treatment of Uveitic Macular Edema
    Rahimi, Mansour
    Shahrzad, Seyed Sahabaldin
    Banifatemi, Mohammad
    IRANIAN JOURNAL OF IMMUNOLOGY, 2012, 9 (02) : 136 - 144
  • [30] Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal)
    Sorrentino, Francesco Saverio
    Bonifazzi, Claudio
    Parmeggiani, Francesco
    PLOS ONE, 2021, 16 (10):